Highest-materiality recent filing
Presentation dated June 3, 2026, furnished as Exhibit 99.1.
BioLife Solutions Q1 revenue up 25% YoY to $27.5M; net income $1.2M
Total revenue $27.5M, +25% YoY from $22.1M; GAAP net income $1.2M vs $0.3M in Q1 2025.
BioLife Solutions issues routine investor presentation; no material news disclosed
Investor presentation released on March 2, 2026, highlights cell-based therapy solutions.
BioLife Solutions Q4 2025 rev $24.8M (+20% YoY), GAAP net income $2.1M; guides 2026 rev $112.5-$115M
Q4 revenue $24.8M (+20% YoY); full-year revenue $96.2M (+29% YoY).
Q4 2025 continuing ops revenue $24.8M, up 20% from $20.7M in Q4 2024.
Karen Foster, Chief Quality and Operations Officer, notified retirement effective March 31, 2026.
Filed an 8-K to furnish investor presentation dated November 17, 2025.
BioLife Q3 total rev $28.1M (+31% YoY); net income $0.6M; raises cell processing guidance to $93-94M
Total Q3 revenue $28.1M (up 31% YoY); Cell Processing revenue $25.4M (up 33% YoY).
BioLife Solutions annual meeting: two directors face >40% withhold votes
All seven director nominees re-elected; Ellingson and Goswami each received >40% withhold votes (19.8M and 17.5M withheld, respectively).
BioLife Solutions Q2 revenue up 29%; raises FY2025 guidance to $100-103M
Total revenue $25.4M (+29% YoY); Cell Processing revenue $23.0M (+28% YoY).
BioLife Solutions Q1 revenue up 30% YoY to $23.9M; net loss narrows to $0.4M
Cell Processing revenue of $21.6M (+33% YoY), driven by biopreservation media demand from commercial therapies.
BioLife appoints Cathy Coste to board as director and audit committee chair
Effective March 18, 2025, Catherine Coste appointed to board, replacing Joydeep Goswami as audit committee chair.
BioLife Solutions Q4 revenue $22.7M (+31% YoY); guides 2025 up 16-20%
Q4 total revenue $22.7M (up 31% YoY); Cell Processing $20.3M (+37% YoY).
BioLife Solutions Q4 preliminary revenue $22.7M, +31% YoY; cell processing beats FY guidance
Q4 2024 continuing ops revenue $22.7M (+31% YoY); cell processing $20.3M (+37% YoY, +7% sequentially).
BioLife Solutions appoints Tony J. Hunt (Repligen Chairman) to board effective Jan 2, 2025
Tony J. Hunt, Executive Chairman of Repligen (Nasdaq: RGEN), appointed to BioLife board.
Sold Custom Biogenic Systems (CBS) to Standex International for ~$6.1M; transaction closed Nov 14, 2024.
BioLife Solutions sells SciSafe for $73M cash; closes Nov 12, 2024
Sold all SciSafe shares to Subzero Purchaser Corp. for $73M; repaid $0.9M of SciSafe debt and paid $3.3M to waive earn-out rights.
BioLife Solutions Q3 revenue up 30% to $30.6M; raises Cell Processing guidance to $72-73M
Q3 revenue $30.6M (+30% YoY); Cell Processing $19.0M (+43% YoY); adjusted EBITDA $6.1M (20% margin).
BioLife Solutions corrects Q2 earnings; raises full-year revenue guidance to $99-101M
Q2 total revenue $28.3M, down 3% YoY but up 6% sequentially; Cell Processing up 11% sequentially.
BioLife Q2 revenue $28.3M (-3% YoY), net loss $7.1M; raises FY24 revenue guidance to $99-101M
Q2 total revenue $28.3M (-3% YoY, +6% seq); Cell Processing $18.0M (+11% seq).
Roderick de Greef, Joydeep Goswami, Amy DuRoss, Rachel Ellingson, and Timothy Moore re-elected as directors.
BioLife Q1 net loss $10.2M; revenue down 16% YoY; divests GCI freezer unit, reaffirms 2024 guidance
Q1 total revenue $31.7M (-16% YoY); Cell Processing $16.2M (+10% seq), Biostorage $7.1M (+25% YoY), Freezers $8.4M (-35% YoY).
BioLife Solutions sells Global Cooling for $1, incurs ~$7.4M cash outflows
Sold Global Cooling for $1.00; provided $4.9M to meet $7M cash closing condition.
BioLife Solutions divests Stirling freezer business for $1; cuts 11% of workforce
Sold Global Cooling (Stirling) for $1.00; expects to eliminate several million dollars of quarterly cash burn.
BioLife Q4 rev $32.7M (-26% YoY); guides 2024 rev $95.5-100M ex-freezer; adj EBITDA positive
Q4 GAAP net loss $13.4M ($0.30 loss/share) vs $49.2M loss ($1.15) in Q4 2022.
Effective March 18, 2025, the board of directors (the “Board”) of BioLife Solutions, Inc. (the “Company”) appointed Catherine Coste to serve as a member of the Board until the Company’s 2025 Annual Meeting of Stockholders
Max materiality 0.80 · Median 0.70 · Most common event earnings